Document is current
Any future updates will be listed below
-
Authors
Shah, Nina
Sussman, Matthew
Crivera, Concetta
Valluri, Satish
Benner, Jennifer
Jagannath, Sundar
-
Funding
Funding for this research was provided by:
Janssen Pharmaceuticals
- License Information
-
More Information
Article History
Accepted: 11 February 2021
First Online: 18 February 2021
Declarations
:
: This research study was funded by Janssen Pharmaceuticals, Inc.
: Nina Shah has received research funding from Bristol-Myers Squibb, Janssen, Bluebird Bio, Sutro Biopharma, Teneobio, Poseida, and Nektar, and has undertaken an advisory role with GSK, Amgen, Indapta Therapeutics, Sanofi, CareDx, Kite, Karyopharm, and Oncopeptides. Matthew Sussman and Jennifer Benner are employees of Panalgo LLC and were paid consultants in connection with the study. Concetta Crivera and Satish Valluri are employees of Johnson & Johnson (J & J) and have in excess of $10,000 of J & J stock. Sundar Jagannath is a consultant for Bristol-Myers Squibb, Karyopharm Therapeutics, Legend Biotech, Sanofi and Takeda.
: This study involved a systematic review of the literature and therefore did not require ethics approval.
: This study involved a systematic review of the literature and therefore did not require patient consent.
: Not applicable.
: This study involved a systematic review of the literature; therefore, all data and materials are publicly available.
: Not applicable.
